Embedded Files
Leading Innovator in Vaccine Platform Technologies
Our Technology
Our Technology
VSE technology replaced Adjuvants in the vaccines
CellenVax has developed an engineering technology known as Viral Surface Engineering (VSE) through years of research, which enhances immune efficiency by attaching immune-enhancing molecules to the virus surface compared to conventional vaccines. The novel vaccine platform, VSE, possesses a high degree of versatility for the development of various virus vaccines, eliminates the need for additional processes in existing vaccine platforms, and offers a distinct advantage of not requiring separate adjuvants.
Our company is currently validating the superiority of our technology through evaluations of diverse human and animal-origin virus diseases utilizing this vaccine platform. Furthermore, the immune responses elicited by the developed vaccines undergo comprehensive clinical analyses targeting various species and organs to assess their safety.
Technology Great Advantages
Technology Great Advantages
Efficacy
Efficacy
With Fc-Fc receptor response induced fast antigen recognition and stimulating various immune cells
Safety
Safety
Without adjuvant, no side effect
Economic
Economic
No change or modification on process
Versality
Versality
Applicable to any viral vaccines as cell line based technology (animal/human DNA/RNA viruses)
CellenVax focuses on developing technologies that prioritize high safety in antibody generation and low vaccine prices, addressing the primary needs of vaccine consumers. We are confident that our emphasis on these aspects will secure a competitive position in the existing vaccine market and garner high preference among business partners for CellenVax's technology.
Page updated
Google Sites
Report abuse